Background and requirements of the EU Falsified Medicines Directive (FMD)
Since 9th of February 2019, three years after the publication of the EU-wide Act 2011/62, prescription medicines can only be marketed in the EU if they meet the requirements of the European Falsified Medicines Directive. From now on, all affected prescription medicines must be labeled with a so-called Unique Identifier (2D Data Matrix Code including serial number) in connection with individual production data (product identification GTIN / NTIN / PPN, expiry date and batch number) on each folding box. This distinctive labeling makes each packing unit clearly identifiable and traceable throughout Europe Union. In addition, each packing unit is sealed with Tamper Evident labels, as a first opening protection. Pharmacies are required to electronically check these new security features in order to ensure that only original products, which were officially released for market sales, are hand over to the end customer. Hence, the primary goal of this EU directive is to improve the protection of patients by preventing the entry of counterfeits into the legal supply chain of pharmaceuticals. Similar and sometimes even more extensive regulations apply in many countries of the world or are in preparation.
How do we meet the requirements of the EU Falsified Medicines Directive (FMD)?
You see, we are well prepared! Do not hesitate to contact us with further questions.